Search company, investor...

Predict your next investment

Vesalius BioCapital company logo
Venture Capital
vesaliusbiocapital.com

Investments

53

Portfolio Exits

10

Funds

6

About Vesalius BioCapital

Vesalius BioCapital Partners invests in companies active in human health through venture capital funds. The company was founded in 2007 and is based in Strassen, Luxembourg.

Headquarters Location

1B rue Thomas Edison

Strassen, 1445,

Luxembourg

+352 26 84 56 82

Want to inform investors similar to Vesalius BioCapital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Vesalius BioCapital News

Vesalius Biocapital announces first close of its fourth fund securing over €95 Million

Jul 13, 2023

Vesalius Biocapital announces first close of its fourth fund securing over €95 Million 13 July 2023 Vesalius Biocapital , the specialist life sciences venture capital investor, announces the first close of its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments. The fund has attracted blue chip investors including the European Investment Fund (EIF). Starting immediately Vesalius Biocapital IV is to invest in first and best-in-class European life science companies in drug development and digital health. The goal is to build a well-balanced portfolio of 10-15 companies, providing capital and the Vesalius team’s experience and expertise to support their development. Now in its sixteenth year, Vesalius Biocapital has a successful track record of backing highly innovative companies and has raised over €270 million from a renowned investor base for its three previous funds. It has completed over 30 investments with lead or co-lead positions and achieved numerous exits through trade sales and IPOs. These include: Forendo, acquired by Organon; Sword Health sold to a group of private equity investors; Apitope acquired by Chinese company Worg Pharma; and Ogeda acquired by Astellas Pharma. With a well-balanced portfolio between drug development and non-drug development investments, Vesalius has a successful track-record of strong and consistent financial performance and has generated significant returns for its investors. Commenting on the first close, Stéphane Verdood , Managing Partner at Vesalius Biocapital IV said:“Our successful track record placed us in a strong position to attract high quality investors such as the EIF (European Investment Fund) to Vesalius Biocapital IV. Furthermore, it is fantastic validation of our investment approach and strategy that a significant number of investors in our previous funds are backing us in Vesalius Biocapital IV. This is an exciting time in healthcare; the industry is at a key inflection point between science, technology and medicine, and our investors support our strategy to invest in companies developing innovative first in class products and technologies.” Marjut Falkstedt , Chief Executive Officer at the European Investment Fund, added: “The development of new therapies and digital health solutions are revolutionising the healthcare sector, but these innovations need targeted, dedicated investment. The EIF is glad to partner with Vesalius for its fourth fund, building on a strong track record in the sector, which also aims to channel investment towards underserved areas in the innovation landscape, particularly in southern Europe.” Vesalius Biocapital IV is targeting €150M and will accept new investors on a “rolling closing” basis until the final closing in 2024.

Vesalius BioCapital Investments

53 Investments

Vesalius BioCapital has made 53 investments. Their latest investment was in OncoDNA as part of their Series C on July 7, 2023.

CBI Logo

Vesalius BioCapital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/3/2023

Series C

OncoDNA

$7.09M

No

2

11/22/2022

Series C

CatalYm

$51M

No

16

3/10/2022

Series A - II

Scenic Biotech

$31M

Yes

9

2/16/2022

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

10/12/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/3/2023

11/22/2022

3/10/2022

2/16/2022

10/12/2021

Round

Series C

Series C

Series A - II

Series B - II

Series B

Company

OncoDNA

CatalYm

Scenic Biotech

Subscribe to see more

Subscribe to see more

Amount

$7.09M

$51M

$31M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

16

9

10

10

Vesalius BioCapital Portfolio Exits

10 Portfolio Exits

Vesalius BioCapital has 10 portfolio exits. Their latest portfolio exit was Humedics on January 04, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/4/2023

Acquired

$99M

3

11/11/2021

Acquired

$99M

10

8/18/2021

Acquired

$99M

2

6/7/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

5/30/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/4/2023

11/11/2021

8/18/2021

6/7/2019

5/30/2018

Exit

Acquired

Acquired

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

10

2

10

10

Vesalius BioCapital Fund History

6 Fund Histories

Vesalius BioCapital has 6 funds, including Vesalius BioCapital Fund IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/29/2023

Vesalius BioCapital Fund IV

$103.73M

1

6/25/2019

Vesalius BioCapital III

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2013

Vesalius Bicapital II

Subscribe to see more

Subscribe to see more

$99M

10

10/31/2008

Vesalius Biocapital Partners I

Subscribe to see more

Subscribe to see more

$99M

10

Vesalius Biocapital I

$99M

10

Closing Date

6/29/2023

6/25/2019

12/31/2013

10/31/2008

Fund

Vesalius BioCapital Fund IV

Vesalius BioCapital III

Vesalius Bicapital II

Vesalius Biocapital Partners I

Vesalius Biocapital I

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$103.73M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Vesalius BioCapital Team

4 Team Members

Vesalius BioCapital has 4 team members, including , .

Name

Work History

Title

Status

Alain Parthoens

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Alain Parthoens

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.